Kalehua Capital Management
Kalehua Capital Management reported 26 stocks worth $313M in its 13F filing for Q2 2026, filed Aug 19, 2026. Its largest holdings are MANE (11.4%), XFOR (11.1%) and BOXX (8.4%). Compared with Q1 2026, the fund opened new positions in KPTI, IFRX and NVCT, added to MANE, ACRS and IKT, trimmed BOXX, QURE and TIL and sold out of RLAY, ORKA and PEPG.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  MANE Veradermics Inc | $35.8M | 11.4% | 291K | +43K (+17%) | 2 of 3 | |
| 2 |  XFOR X4 Pharmaceuticals Inc | $34.8M | 11.1% | 7.4M | No change | 3 of 3 | |
| 3 |  BOXX EA Series Trust | $26.5M | 8.4% | 226K | −111K (−33%) | 3 of 3 | |
| 4 |  CMPS Compass Pathways PLC | $23.2M | 7.4% | 1.6M | No change | 3 of 3 | |
| 5 |  SRZN Surrozen Inc | $20M | 6.4% | 770K | No change | 3 of 3 | |
| 6 |  ACRS Aclaris Therapeutics Inc | $19.4M | 6.2% | 3.7M | +495K (+16%) | 2 of 3 | |
| 7 |  SION Sionna Therapeutics Inc | $17.3M | 5.5% | 394K | No change | 3 of 3 | |
| 8 |  IKT Inhibikase Therapeutics Inc | $15.5M | 5.0% | 7.6M | +1.1M (+18%) | 3 of 3 | |
| 9 |  PHVS Pharvaris N V | $13.7M | 4.4% | 398K | No change | 3 of 3 | |
| 10 |  KPTI Karyopharm Therapeutics Inc | $13.4M | 4.3% | 1.4M | New position | 1 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 RLAY Relay Therapeutics Inc | $17.9M | 1.8M |
 ORKA Oruka Therapeutics Inc | $11.6M | 237K |
 PEPG Pepgen Inc | $3.1M | 1.7M |
 TNYA Tenaya Therapeutics Inc | $2.8M | 4M |
 KLRS Kalaris Therapeutics Inc | $1.6M | 271K |
🔒 Free account: see all 7.
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 19, 2026 | 13F-HR/A Amendment | Q2 2026 | SEC filing ↗ |
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Includes an amendment, which can add positions the fund kept confidential at first, or replace the original report.
Other superinvestors
All hedge fund holdings →Kalehua Capital Management 13F FAQ
What does Kalehua Capital Management own?
Kalehua Capital Management reported 26 stocks worth $313M in its 13F filing for Q2 2026, filed Aug 19, 2026. Its largest holdings are MANE (11.4%), XFOR (11.1%) and BOXX (8.4%). The table above lists every position in the filing (the top 10 without an account).
What did Kalehua Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 8 new positions, 5 added to, 3 trimmed and 7 sold out. New positions include KPTI, IFRX and NVCT. It sold all of RLAY, ORKA and PEPG.
When will Kalehua Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Kalehua Capital Management's portfolio worth?
The Q2 2026 filing reports $313M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.